Suction-type mPEG-PLGA / FK506 drug-loaded nanoparticles as well as preparation method and application thereof

The preparation of mPEG-PLGA/FK506 drug-loaded nanoparticles was solved through the emulsification-solvent volatility method of mPEG-PLGA/FK506 drug-loaded nanoparticles, and the problem of toxic side effects and low bioavailability in the administration method of FK506 was achieved, and the slow release of FK506 was achieved and the effective treatment of chronic post-pulmonary transplantation was achieved. Transplant lung rejection reaction.

CN118948810APending Publication Date: 2024-11-15SICHUAN UNIV
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411015385.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing FK506 administration method has the problems of high toxic side effects and low bioavailability, especially in the treatment of chronic transplant lung rejection caused by lung transplantation after lung transplantation.

Method used

The mPEG-PLGA/FK506 drug-loaded nanoparticles were prepared by emulsification-solvent volatilization method to control the particle size and encapsulation rate of nanoparticles, realize the atomized administration of lungs, reduce the side effects of drug toxicity and delay the progress of chronic transplantation lung dysfunction .

Benefits of technology

It has achieved the slow release effect of FK506, improved bioavailability, reduced drug use dose and toxic side effects, and has good clinical application prospects, and can effectively treat chronic transplanted lung rejection reactions caused by lung transplantation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948810A_ABST
    Figure CN118948810A_ABST
Patent Text Reader

Abstract

The invention provides an inhalation type mPEG-PLGA / FK506 drug-loaded nanoparticle as well as a preparation method and application thereof, and belongs to the field of biomedical materials. The preparation method of the nanoparticles comprises the following steps: (1) dissolving polyvinyl alcohol in water to serve as a water phase; (2) dissolving a methoxy polyethylene glycol polylactic acid-glycolic acid copolymer and tacrolimus in an organic solvent to serve as an oil phase; (3) adding the oil phase into the water phase to prepare an emulsion; and (4) adding the emulsion into a polyvinyl alcohol solution, stirring, volatilizing the organic solvent, centrifuging, and drying to obtain the nanoparticles. The nano-particles provided by the invention can be applied to lung atomization administration, and the nano-particles have good biological safety, have the effect of slowly releasing drugs, can adapt to chronic rejection generated in lung transplantation, and can effectively delay the progress of chronic transplantation lung dysfunction. In addition, the dosage and frequency of medicine use can be reduced, toxic and side effects of the medicine are reduced, and therefore the medicine has good clinical application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomedical materials, and in particular relates to an inhalable mPEG-PLGA / FK506 drug-loaded nanoparticle and a preparation method and application thereof. Background Art

[0002] Lung transplantation is the best treatment for end-stage lung disease. Chronic lung allograft dysfunction (CLAD) caused by chronic lung allograft rejection (CLAR) is the most important factor limiting the long-term survival of lung transplant recipients. Currently, about half of lung transplant recipients suffer from CLAD five years after surgery. The drugs currently used for treatment generally have various toxic side effects, affecting other normal functions of the human body and affecting their application in the clinical field.

[0003] Tacrolimus (FK506) is a neutral hydrophobic macrolide immunosuppressant isolated from Streptomyces tsukuba. It has been widely used to treat solid organ transplant rejection and many other immunological diseases. At present, oral administration is the main route of clinical administration, but oral absorption varies greatly from person to person, bioavailability is 5% to 67%, and absorption is affected by food. Injection administration is highly toxic, with a higher incidence of adverse reactions than oral administration, and is metabolized by the liver, with low drug utilization and many metabolic byproducts. It is of great significance to choose a suitable administration method that can both exert the effect of FK506 and reduce the toxic and side effects of FK506.

[0004] Different from the traditional drug treatment system, drug-loaded nano-microspheres are a type of drug preparation that disperses or encapsulates drugs in materials to form porous or microcapsule-type microspheres, with particle sizes ranging from nanometers to micrometers. The use of biocompatible materials to encapsulate drugs allows some drugs that are unstable or have poor biocompatibility in the body environment to be delivered to specific tissues or organs through drug-loaded nano-microsphere preparations, which can maintain effective drug concentrations in the lesions and control the drug diffusion range within a certain area. Unlike traditional medicine, which requires the intake of large amounts of drugs to achieve the required blood drug concentration, this greatly avoids the toxic side effects that may be induced by high concentrations of drugs in other normal tissues, and reduces the dosage and treatment costs. In addition, the sustained release effect of drug-loaded microspheres can maintain effective drug concentrations in the target range for a long time, achieving a continuous treatment effect, and is an excellent emerging drug delivery system.

[0005] The most commonly used method for preparing microspheres is the emulsification-solvent evaporation method, the principle of which is to dissolve the raw materials and excipients in two immiscible solvents, and then make an emulsion by mechanical oscillation or ultrasonic emulsification. The liquid dispersed into emulsion droplets is the inner dispersed phase, and the liquid dispersing the emulsion droplets is the outer continuous phase. Then, the inner dispersed phase solvent is evaporated and removed under certain conditions, and the spherical material is precipitated and solidified into microspheres. This method has the advantages of high encapsulation rate, simple operation method, good reproducibility, and no need for special equipment, but it is easily affected by factors such as the physical and chemical properties of the encapsulated drug.

[0006] For FK506, the prior art has prepared it into nano-microspheres, see the patent application with application number 2019104611384 for details. The patent records that a non-ionic surfactant is first added to deionized water to form an aqueous phase, PLGA and FK506 are dissolved in an organic solvent in turn to form an oil phase, and then the oil phase is slowly added dropwise to the center of the aqueous phase vortex, and an O / W type emulsion is obtained after high-speed stirring and ultrasonic treatment; the obtained O / W type emulsion is then slowly stirred at room temperature to completely volatilize the organic solvent to obtain a nano-microsphere suspension, and finally centrifuged, washed, and dried to obtain the target product. However, PLGA, as a drug sustained-release carrier, is easily cleared by mononuclear macrophages (MPS) in the human body, and its bioavailability needs to be further improved. In addition, if a drug can be provided to achieve pulmonary administration of FK506, it is also expected to improve the effect of treating chronic transplant lung rejection after lung transplantation. Summary of the invention

[0007] The purpose of the present invention is to provide an inhalable mPEG-PLGA / FK506 drug-loaded nanoparticle and a preparation method and use thereof.

[0008] The present invention provides a method for preparing mPEG-PLGA / FK506 drug-loaded nanoparticles, which comprises the following steps:

[0009] (1) dissolving polyvinyl alcohol in water as the aqueous phase;

[0010] (2) dissolving methoxy polyethylene glycol poly(lactic acid-co-glycolic acid) copolymer and tacrolimus in an organic solvent as an oil phase;

[0011] (3) adding the oil phase of step (2) to the water phase of step (1) to prepare an emulsion;

[0012] (4) adding the emulsion obtained in step (3) into the polyvinyl alcohol solution and stirring to evaporate the organic solvent, then centrifuging and drying to obtain nanoparticles.

[0013] Furthermore, in step (1), the concentration of polyvinyl alcohol in the aqueous phase is 5 to 50 mg / ml;

[0014] and / or, in step (2), the concentration of methoxy polyethylene glycol polylactic acid-glycolic acid copolymer in the oil phase is 5 to 30 mg / ml;

[0015] And / or, in step (2), the mass ratio of the methoxy polyethylene glycol polylactic acid-glycolic acid copolymer to tacrolimus is (1-6):1;

[0016] And / or, in step (3), when the oil phase is added to the water phase, the volume ratio of the oil phase to the water phase is (2-4):8;

[0017] And / or, in step (3), shearing is performed when the oil phase is added to the water phase, and ultrasonic dispersion is performed after the oil phase is added to the water phase.

[0018] Furthermore, in step (1), the concentration of polyvinyl alcohol in the aqueous phase is 10 mg / ml;

[0019] and / or, in step (2), the concentration of methoxy polyethylene glycol polylactic acid-glycolic acid copolymer in the oil phase is 7 mg / ml;

[0020] And / or, in step (2), the mass ratio of the methoxy polyethylene glycol poly(lactic acid-glycolic acid) copolymer to tacrolimus is 2:1;

[0021] And / or, in step (2), the organic solvent is dichloromethane;

[0022] And / or, in step (3), when the oil phase is added to the water phase, the volume ratio of the oil phase to the water phase is 1:4.

[0023] Further,

[0024] In step (3), the shearing speed when the oil phase is added to the water phase is 12000-20000 rpm, and the shearing time is 15-60 min; preferably, the shearing speed is 15000 rpm, and the shearing time is 30 min;

[0025] And / or, in step (3), the ultrasonic dispersion time after adding the oil phase into the water phase is 1 to 5 minutes.

[0026] Furthermore, in step (4), the polyvinyl alcohol solution is a polyvinyl alcohol aqueous solution with a concentration of 0.1%;

[0027] and / or, in step (4), the volume ratio of the emulsion to the polyvinyl alcohol solution is 1:2;

[0028] And / or, in step (4), the stirring temperature is 25 to 30° C., and the stirring time is 2 to 6 hours;

[0029] And / or, in step (4), the stirring speed is 600 to 3000 rpm;

[0030] And / or, in step (4), the centrifugal speed is 10000-12000 rpm, and the centrifugal time is 10-30 min;

[0031] Preferably, in step (4), the stirring speed is 2400 rpm.

[0032] The present invention also provides a mPEG-PLGA / FK506 drug-loaded nanoparticle, which is prepared by the above-mentioned preparation method.

[0033] Furthermore, the average particle size of the mPEG-PLGA / FK506 drug-loaded nanoparticles is 100 to 210 nm.

[0034] The present invention also provides the use of the aforementioned mPEG-PLGA / FK506 drug-loaded nanoparticles in the preparation of aerosol drug delivery preparations.

[0035] Furthermore, the drug delivery preparation is a pulmonary aerosol drug delivery preparation.

[0036] Furthermore, the preparation is a preparation for treating chronic transplant lung rejection produced after lung transplantation;

[0037] Preferably, the preparation is a preparation for chronic allograft pulmonary dysfunction.

[0038] Compared with the prior art, the present invention has the following beneficial effects:

[0039] The present invention provides a mPEG-PLGA / FK506 drug-loaded nanoparticle. The present invention selects specific preparation conditions to achieve the desired particle size, encapsulation rate and drug loading rate of the obtained nanoparticles, thereby ensuring the feasibility of pulmonary atomization of the nanoparticles; the nanoparticles themselves have good biosafety and have the effect of slowly releasing drugs, can adapt to chronic rejection reactions produced in lung transplantation, and can effectively delay the progression of chronic transplantation lung dysfunction; in addition, the dosage and frequency of drug use can be reduced, and the drug toxicity and side effects can be reduced, so it has good clinical application prospects.

[0040] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.

[0041] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 is the standard curve of FK506.

[0043] Figure 2 The macroscopic images, particle size, encapsulation efficiency and drug loading rate results of nanoparticles prepared with different mPEG-PLGA concentrations in group A: A is the particle size result diagram of each group of nanoparticles; B is the encapsulation efficiency and drug loading rate result diagram of each group of nanoparticles; C is the macroscopic image of each group of nanoparticles dispersed in water.

[0044] Figure 3 The macroscopic images, particle size, encapsulation efficiency and drug loading rate results of the nanoparticles prepared at different high-speed shear speeds in groups B and D: A is the particle size results of the nanoparticles in each group; B is the encapsulation efficiency and drug loading rate results of the nanoparticles in each group; C is the macroscopic image of the nanoparticles in each group dispersed in water.

[0045] Figure 4 The particle size, encapsulation efficiency and drug loading rate result graphs of nanoparticles prepared with different concentrations of non-ionic surfactant (PVA solution): A is the particle size result graph of each group of nanoparticles; B is the encapsulation efficiency and drug loading rate result graph of each group of nanoparticles; among them, 5% PVA is group G2 in Table 1, and 1% PVA is group D1 in Table 1.

[0046] Figure 5 The graphs show the particle size, encapsulation efficiency and drug loading rate of the nanoparticles prepared with different organic solvents in group E: A shows the particle size of the nanoparticles in each group; B shows the encapsulation efficiency and drug loading rate of the nanoparticles in each group.

[0047] Figure 6 The graphs show the particle size, encapsulation efficiency and drug loading rate of nanoparticles prepared with different mPEG-PLGA and FK506 mass ratios in group G: A is the particle size result graph of each group of nanoparticles; B is the encapsulation efficiency and drug loading rate result graph of each group of nanoparticles.

[0048] Figure 7 This is a graph showing the particle size results of the nanoparticles prepared under the optimal conditions screened by the orthogonal experiment in Table 2.

[0049] Figure 8 The particle size and Zeta potential results of nanoparticles before and after loading FK506: A is the particle size result; B is the Zeta potential result.

[0050] Fig. 9SEM and TEM images of nanoparticles: A is SEM; B is TEM.

[0051] Fig.10 The drug release results of nanoparticles prepared with different mPEG-PLGA and FK506 mass ratios.

[0052] Fig.11 The drug release results of mPEG-PLGA / FK506 drug-loaded nanoparticles; A is the drug release result within 168 hours; B is the drug release result within 720 hours.

[0053] Fig.12 This is a graph showing the toxicity test results of mPEG-PLGA nanoparticles on human bronchial epithelial cells.

[0054] Fig.13 Staining results for cellular uptake.

[0055] Fig.14 The CCK8 detection results of mPEG-PLGA / FK506 drug-loaded nanoparticles with different tacrolimus drug concentrations on lung cell viability assay; ns in the figure indicates no significant difference compared with the 0nM group (P>0.05); * indicates a significant difference compared with the 0nM group (P<=0.05).

[0056] Fig.15 The live and dead cell staining results of donor lung cells by mPEG-PLGA / FK506 drug-loaded nanoparticles with different tacrolimus drug concentrations: the upper figure is the live and dead staining fluorescence image; the lower figure is the statistical result of cell survival rate; in the figure, * indicates a significant difference compared with the 0nM group (P<0.05); ** indicates a very significant difference compared with the 0nM group (P<=0.01).

[0057] Fig.16 This is the in vivo imaging of animals after aerosol inhalation of fluorescent drug-loaded nanoparticles; the left picture is repetition 1; the middle picture is repetition 2; and the right picture is repetition 3.

[0058] Fig.17 The figures show the gross appearance of the lungs of rats after treatment with different concentrations of drugs, as well as HE staining and MASSON staining and semi-quantitative evaluation of pathological results; A shows the gross appearance of the lungs (Macro), HE staining of lung tissue (HE), and MASSON staining of lung tissue (MT); B shows the percentage of collagen fibers in transplanted lung tissues of each group (left figure), perivascular fibrosis rating (middle figure), and International Society for Heart and Lung Transplantation A grade (right figure); * indicates significant difference (P<0.05); ** indicates extremely significant difference (P<=0.01); *** indicates extremely significant difference (P<=0.001); **** indicates extremely significant difference (P<=0.0001). DETAILED DESCRIPTION

[0059] The raw materials and equipment used in the specific embodiments of the present invention are all known products and are obtained by purchasing commercially available products.

[0060] Polyvinyl alcohol (PVA): weight average molecular weight (Mw) 30000-70000, 87-90% hydrolyzed.

[0061] Methoxy polyethylene glycol poly(lactic acid)-co-glycolic acid (mPEG-PLGA): mPEG5K-PLGA50 / 50Mw30K.

[0062] Example 1. Preparation of mPEG-PLGA / FK506 drug-loaded nanoparticles of the present invention

[0063] The preparation method of mPEG-PLGA / FK506 drug-loaded nanoparticles of the present invention comprises the following steps:

[0064] (1) Add nonionic surfactant polyvinyl alcohol (PVA) into deionized water and dissolve it uniformly to obtain a PVA solution as the aqueous phase. The concentration of PVA in the PVA solution is shown in Table 1.

[0065] (2) Methoxy polyethylene glycol poly (lactic acid-co-glycolic acid) copolymer (mPEG-PLGA) and tacrolimus (FK506) were added to the organic solvent in sequence, and after being completely dissolved, a uniform mixed solution was formed as the oil phase. The amounts of mPEG-PLGA, FK506 and the organic solvent, as well as the concentration of mPEG-PLGA in the organic solvent, the mass ratio of mPEG-PLGA and FK506, and the type of the organic solvent are shown in Table 1.

[0066] (3) Under ice bath (0°C) and high-speed shearing conditions, the oil phase obtained in step (2) is added dropwise to the center of the water phase vortex in step (1) to form colostrum; and the colostrum is further ultrasonically dispersed under ice bath conditions for 1 min to obtain an O / W type emulsion. The high-speed shearing speed, high-speed shearing time, volume of the oil phase and the water phase, and the volume ratio are shown in Table 1.

[0067] (4) Remove the ice bath, add 20 ml of 0.1% PVA aqueous solution to the O / W emulsion obtained in step (3), stir at constant temperature (25° C.) for 6 h at room temperature to evaporate the organic solvent to obtain a nanosphere suspension, then centrifuge at high speed (12000 rpm, centrifugation time 10 minutes) to collect the product (precipitate after centrifugation), wash the product with ddH2O 3 times and then vacuum dry to obtain the mPEG-PLGA / FK506 drug-loaded nanospheres. The constant temperature stirring speed is shown in Table 1.

[0068] Table 1. Parameters for preparing mPEG-PLGA / FK506 drug-loaded nanoparticles in Example 1

[0069]

[0070]

[0071] In order to explore the effects of different conditions on the particle size, encapsulation efficiency and drug loading rate of nanoparticles, experiments were conducted in groups. The variable of group A was the concentration of mPEG-PLGA, the variables of groups B and D were both high-speed shear speed, the variable of group C was the stirring speed of evaporating organic solvent, the variable of group E was organic solvent, the variable of group F was the shear time of high-speed shear, and the variable of group G was the mass ratio of mPEG-PLGA to FK506. The particle size, encapsulation efficiency and drug loading rate of the nanoparticles prepared in each group were detected.

[0072] (1) The method for determining the particle size of nanoparticles is as follows:

[0073] The particle size was measured by dynamic light scattering (DLS). The concentration of the nanoparticle aqueous solution to be tested was 1 mg mL -1 , take 1 ml into a quartz cuvette, mix well, put it into the sample cell, and use a Zetasizer nanoparticle size potential analyzer to measure the particle size distribution; set the scattering angle to 90°, the test temperature to 25°C, and repeat the test 3 times for each sample.

[0074] Nanocarriers with sizes less than 200 nm could theoretically evade detection by alveolar macrophages, leading to more efficient uptake and action.

[0075] (2) The method for determining the encapsulation efficiency and drug loading rate is as follows:

[0076] Methanol and FK506 were used to prepare 25, 50, 100, 200, 300, and 400 μg / mL standard solutions, which were transferred to injection bottles, respectively, and tested on the machine. The mobile phase was acetonitrile and 0.1% phosphonic acid aqueous solution (70:30, volume ratio), column temperature was 50°C, flow rate was 1 ml / min, injection volume was 10 μl, detection wavelength was 210 min, detection time was 20 min, retention time was 11.6 min, and the high performance liquid chromatography column was used to prepare a standard curve according to the peak area and drug concentration determined by HPLC ( Figure 1 ), and the encapsulation efficiency and drug loading rate were determined according to the standard curve.

[0077] The particle size, encapsulation efficiency and drug loading rate of mPEG-PLGA / FK506 drug-loaded nanoparticles prepared in each group are shown in Table 1 and Figures 2 to 6 As shown in Table 1 and Figure 2 It can be seen that the concentration of mPEG-PLGA has little effect on the particle size of nanoparticles. As the concentration increases, the encapsulation rate first decreases and then increases, and the drug loading rate decreases. Figure 3 It can be seen that a shear rate of 15000rpm can produce nanoparticles with smaller particle sizes; Figure 4 It can be seen that the higher the concentration of PVA, the better the dispersion of the prepared nanoparticles, but high concentrations have toxicity problems; from Table 1 and Figure 5 It can be seen that the nanoparticles made with dichloromethane as the oil phase solvent are better than those made with dichloromethane + acetone; Figure 6 It can be seen that the larger the mass ratio of mPEG-PLGA to FK506, the smaller the particle size, the greater the encapsulation efficiency, and the smaller the drug loading rate. In addition, it can be seen from Table 1 that the constant temperature stirring speed and shear time also have an effect on the particle size, encapsulation efficiency and drug loading rate of the prepared nanoparticles.

[0078] Since various preparation conditions may affect each other, orthogonal experiments were further conducted to explore the effects of PVA concentration, the concentration of mPEGPLGA in organic solvent (mPEGPLGA concentration), the volume ratio of oil phase and water phase (oil-water ratio), and constant temperature stirring speed (evaporation speed) on the particle size, encapsulation efficiency and drug loading rate of nanoparticles.

[0079] Example 2: Orthogonal Experimental Study on the mPEG-PLGA / FK506 Drug-Carrying Nanoparticles of the Present Invention

[0080] Based on Example 1, the ratio of mPEG-PLGA:FK506 was fixed at 2:1, the organic solvent was dichloromethane, the high-speed shear speed was 15000 rpm, and the shear time was 30 min. Then, orthogonal experiments were conducted to explore the effects of PVA concentration, mPEGPLGA concentration in organic solvent (mPEGPLGA concentration), oil phase and water phase volume ratio (oil-water ratio), and constant temperature stirring speed (evaporation speed) on the particle size, encapsulation efficiency, and drug loading rate of mPEG-PLGA / FK506 drug-loaded nanoparticles. In the orthogonal experiment, the PVA concentration was selected as follows: 1 = 5% PVA (50 mg / ml), 2 = 0.5% PVA (5 mg / ml), 3 = 1% PVA (10 mg / ml); the mPEGPLGA concentration was selected as follows: 1 = 10 mg / ml, 2 = 7 mg / ml, 3 = 5 mg / ml; the oil-water ratio was 1 = 4:8, 2 = 3:8, 3 = 2:8; the evaporation speed was 1 = 2400 rpm, 2 = 1500 rpm, 3 = 600 rpm. The orthogonal experimental factor level selection and the results of particle size, encapsulation efficiency and drug loading rate are shown in Table 2.

[0081] Table 2. Selection of factor levels in orthogonal experiments and results of particle size, encapsulation efficiency and drug loading rate

[0082]

[0083] According to multi-factor screening, the optimal conditions are: PVA concentration: 1% PVA, mPEGPLGA concentration: 7mg / ml, oil-water ratio: 2:8 (1:4), evaporation speed: 2400rpm, the obtained nanoparticles have a small particle size of 208.7nm and good dispersibility ( Figure 7 ), and is conducive to absorption.

[0084] According to the method described in Example 1, mPEG-PLGA / FK506 drug-loaded nanoparticles (FK506 NPs) were prepared using the optimal conditions selected above (PVA concentration was 1% PVA, mPEGPLGA concentration was 7 mg / ml, oil-water ratio was 2:8, volatilization speed was 2400 rpm, mPEG-PLGA and FK506 mass ratio was 2:1, organic solvent was dichloromethane, high-speed shear speed was 15000 rpm, and shear time was 30 min). At the same time, according to the method described in Example 1, nanoparticles (NPs) without FK506 were prepared using the optimal conditions selected above, and FK506 was not added when preparing NPs.

[0085] The particle size and Zeta potential of FK506 NPs and NPs were determined as follows:

[0086] The particle size and Zeta potential of the nanoparticles were measured by dynamic light scattering (DLS). The concentration of the nanoparticles in the aqueous solution was 1 mg mL -1 , take 1 ml into a quartz cuvette, mix well, put it into the sample cell, and use a Zetasizer nanoparticle size potential analyzer to measure the particle size distribution; set the scattering angle to 90°, the test temperature to 25°C, and repeat the test 3 times for each sample.

[0087] Take another 0.5 mL of nanoparticle aqueous solution into a quartz cuvette, add it to the U-shaped potential cup, mix well, put it into the sample cell, measure the zeta potential, set the scattering angle to 90°, the test temperature to 25°C, and repeat the test 3 times for each sample.

[0088] The particle size and Zeta potential of nanoparticles before and after loading with FK506 are shown in the figure. Figure 8 As shown: After the nanoparticles are loaded with drugs, the particle size will increase slightly (the particle size of FK506 NPs is 208.7nm), and the Zeta potential will increase (the Zeta potential of FK506 NPs is -16.1mV), but they are all negatively charged. This shows that the nanoparticles are stable and can still escape the detection of alveolar macrophages and be better absorbed.

[0089] Fig. 9 These are the SEM and TEM images of the prepared FK506 NPs, indicating that the nanoparticles have good dispersion and uniform particle size.

[0090] The beneficial effects of the present invention are demonstrated below through specific test examples.

[0091] Experimental Example 1: In vitro release effect of mPEG-PLGA / FK506 drug-loaded nanoparticles of the present invention

[0092] According to the method described in Example 1, the optimal conditions screened out in Example 2 were adopted (PVA concentration was 1% PVA, mPEGPLGA concentration was 7 mg / ml, oil-water ratio was 2:8, volatilization speed was 2400 rpm, organic solvent was dichloromethane, high-speed shear speed was 15000 rpm, shear time was 30 min), and only the mass ratio of mPEG-PLGA and FK506 was changed to 4:1, 4:2 and 4:3 to prepare mPEG-PLGA / FK506 drug-loaded nanoparticles, and their in vitro release was measured.

[0093] Weigh 1 mg of FK506 and dissolve it in 1 mL of anhydrous ethanol. According to the drug loading rate, weigh the nanoparticles with the same drug mass (1 mg of FK506) and dissolve them in 2 ml of PBS. Prepare 1xPBS and add 0.5% Tween 80 as a cosolvent. Place the samples in dialysis bags, seal both ends with dialysis clamps, and soak the entire dialysis bag in a centrifuge tube containing 10 ml of 1xPBS. Place the centrifuge tube on a constant temperature shaker with a speed of 100 rpm and a temperature of 37°C. Sampling time points are 12h, 24h, 48h, 72h, 96h, 120h, 144h and 168h. Take 1 ml of the liquid and place it in a 2 ml centrifuge tube and add 1 ml of PBS to the release system again. Put it into the injection bottle and detect the FK506 content on the machine. The drug release curve is shown in Figure 2. Fig.10 shown.

[0094] Depend on Fig.10 It can be seen that: as the input of FK506 increases, its release becomes slower, and the drug sustained-release effect is best when the mass ratio of mPEG-PLGA and FK506 is 4:2 or 4:3. At the same time, considering the particle size of the nanoparticles, in order to match the treatment method of chronic transplant lung dysfunction, the mass ratio of mPEG-PLGA and FK506 was 4:2 (2:1) for subsequent experiments to further verify the sustained-release effect of the nanoparticles.

[0095] The nanoparticles (FK506@mPEG-PLGANPs) prepared with a mass ratio of mPEG-PLGA to FK506 of 4:2 were used to verify the drug sustained release effect. 1 mg of FK506 was weighed and dissolved in 1 mL of anhydrous ethanol. According to the drug loading rate, the nanoparticles with the same drug mass (1 mg of FK506) were weighed and dissolved in 2 ml of PBS. 1xPBS was prepared and 0.5% Tween80 was added as a cosolvent. The samples were placed in dialysis bags, both ends were sealed with dialysis clamps, and the entire dialysis bag was immersed in a centrifuge tube containing 10 ml of 1xPBS. The centrifuge tube was placed on a constant temperature shaker with a speed of 100 rpm and a temperature of 37°C. The sampling time points were 4h, 8h, 16h, 24h, 48h, 72h, 96h, 120h, 144h, 168h, 240h, 288h, 336h, 384h, 456h, 528h, 600h, 648h, and 720h. 1 ml of the liquid was placed in a 2 ml centrifuge tube and 1 ml was added again. PBS was added to the release system and then to the injection bottle, and the FK506 content was tested on the machine. Fig.11 shown.

[0096] Depend on Fig.11 It can be seen that the nanoparticles can achieve a sustained release effect and can be used as a therapeutic method for chronic transplant lung dysfunction.

[0097] Test Example 2: Biosafety Test of the mPEG-PLGA / FK506 Drug-Carrying Nanoparticles of the Present Invention

[0098] (1) Cytotoxicity

[0099] According to the method described in Example 1, the optimal conditions screened out in Example 2 were adopted (PVA concentration was 1% PVA, mPEGPLGA concentration was 7 mg / ml, oil-water ratio was 2:8, volatilization speed was 2400 rpm, organic solvent was dichloromethane, high-speed shear speed was 15000 rpm, shear time was 30 min), and blank mPEG-PLGA nanoparticles were prepared without adding FK506.

[0100] Take a certain amount of dry blank mPEG-PLGA nanoparticles, place them under ultraviolet irradiation for sterilization, prepare medium containing blank mPEG-PLGA nanoparticles of different concentrations (0, 0.2, 1, 2 mg / ml), culture human bronchial epithelial cells, set up three different time points of 1, 2, and 3 days in 96-well plates, and set up blank groups (Control, i.e. 0 mg / ml) and 3 concentrations (0.2, 1, 2 mg / ml) as experimental groups at each time point, and 5 parallels for each concentration. After marking the groups, add 100 μL of full culture solution with cells to each well at a number of 2000 cells / well, and place them in a 37°C, 5% CO2 constant temperature cell culture incubator overnight to allow the cells to adhere to the wall and grow. The next day, after confirming the cell adherence growth with a cell microscope, replace the medium with nanoparticles and culture for 1d, 2d, and 3d before CCK8 detection. The relevant operations of the cell experiment need to be aseptically operated in the cell room, and always pay attention to disinfection and sterilization to prevent bacteria from causing unnecessary effects on the experimental results.

[0101] Depend on Fig.12 The results show that the carrier material of the mPEG-PLGA / FK506 drug-loaded nanoparticles of the present invention has low cytotoxicity and good biosafety.

[0102] (2) Cellular uptake

[0103] According to the method described in Example 1, mPEG-PLGA / FK506 drug-loaded nanoparticles were prepared using the optimal conditions screened out in Example 2 (PVA concentration of 1% PVA, mPEGPLGA concentration of 7 mg / ml, oil-water ratio of 2:8, volatilization speed of 2400 rpm, mass ratio of mPEG-PLGA and FK506 of 2:1, organic solvent of dichloromethane, high-speed shear speed of 15000 rpm, shear time of 30 min). When preparing mPEG-PLGA / FK506 drug-loaded nanoparticles, CY-5-labeled FK506 was used to replace ordinary FK506.

[0104] Take a certain amount of dried fluorescent mPEG-PLGA / FK506 drug-loaded nanoparticles, place them under ultraviolet irradiation for sterilization, prepare a medium with a concentration of 1mg / ml fluorescent mPEG-PLGA / FK506 drug-loaded nanoparticles, culture human bronchial epithelial cells, set up 3 duplicate wells in a 24-well plate, culture at a number of 8000 cells / well, and place them in a 37°C, 5% CO constant temperature cell culture incubator overnight to allow the cells to adhere to the wall and grow. The next day, after confirming the cell adhesion growth with a cell microscope, replace the medium with nanoparticles. After 24 hours of culture, use a live cell dye to stain the cells, and use an inverted fluorescence microscope to observe the cell's uptake of nanoparticles. The relevant operations of the cell experiment need to be aseptically operated in the cell room, and always pay attention to disinfection and sterilization to prevent contamination from causing unnecessary effects on the experimental results.

[0105] The results are as follows Fig.13 As shown, it indicates that the drug-loaded nanoparticles successfully entered the cells within 24 hours.

[0106] Experimental Example 3: In vitro efficacy experiment of mPEG-PLGA / FK506 drug-loaded nanoparticles of the present invention

[0107] According to the method described in Example 1, the optimal conditions screened out in Example 2 (PVA concentration of 1% PVA, mPEGPLGA concentration of 7 mg / ml, oil-water ratio of 2:8, volatilization speed of 2400 rpm, mass ratio of mPEG-PLGA and FK506 of 2:1, organic solvent of dichloromethane, high-speed shear speed of 15000 rpm, shear time of 30 min) were used to prepare mPEG-PLGA / FK506 drug-loaded nanoparticles for the following experiment.

[0108] 1. Preparation of recipient spleen cell suspension

[0109] Brown Norway rats were killed by overdose anesthesia, soaked in 75% alcohol for 3 minutes, transferred to the clean bench, dissected, lungs were taken, and blood stains on the surface were washed with sterile saline. The spleen was cut into small pieces of about 0.5-1 cm, placed on a 70μm cell sieve, 2ml F-12K+10% FBS+P / S was added, and the 1ml syringe push handle was used to gently grind until only part of the connective tissue remained. The grinding solution was transferred to a 15ml centrifuge tube and fixed to 4ml with F-12K+10% FBS+P / S. Centrifuged at room temperature for 5 minutes. The supernatant was discarded, and 2ml of red blood cell lysis solution was added to the precipitate. At room temperature for 3 minutes, 2ml of F-12K+10% FBS+P / S was added to stop the lysis of red blood cells, and passed through a 40μm cell sieve. Centrifuged at room temperature for 5 minutes. Resuspended with 4ml F-12K+10% FBS+P / S. Take the single cell suspension of the recipient spleen and count it with a blood cell counting plate (automatic counting is not allowed, accurate quantification is required). According to the counting results, adjust the concentration of the single cell suspension to 1*10 6 Pieces / ml.

[0110] 2. Preparation of donor lung cells

[0111] The spontaneously immortalized lung epithelial L2 cell line from Lewis rats was selected and cultured using the F-12K+10% FBS system. Cells from passages 4 to 8 were selected for the experiment. 5 The cells were inoculated in a 96-well plate and cultured for 24 hours until they adhered to the wall and grew to 50% of the area. The 96-well plate contained 200 μl of F-12K+10% FBS+P / S system.

[0112] 3. Bidirectional mixed cell reaction and donor injury assessment

[0113] Add 20 μl of 1*10 6 / ml Brown Norway rat spleen cells, then each group was added with 0nM, 10nM, 20nM, 40nM, 80nM, 100nM, 150nM, 200nM tacrolimus-loaded mPEG-PLGA nanoparticles (mPEG-PLGA / FK506 drug-loaded nanoparticles) and cultured for 3 days. The supernatant was aspirated, gently washed once with PBS, 100μl F-12K+10% FBS+P / S+10% CCK8 was added, and cultured at 37℃ for 30min. The OD was quantified by microplate reader to determine the viability of donor cells. Parallel plates were treated in the same way, the supernatant was aspirated, gently washed once with PBS, and Calcein / PI double staining kit (Elabscience) was used to observe and take pictures under an inverted fluorescence microscope to count the number of dead and live cells and the viability.

[0114] 4. Experimental results

[0115] Donor lung cell viability assay

[0116] CCK8 was used to measure the viability of donor lung epithelial cells 3 days after bidirectional cell mixing. The results were ( Fig.14 ) found that the ratio of OD450nm of donor lung cells in the mPEG-PLGA / FK506 drug-loaded nanoparticles treatment group with tacrolimus drug concentrations of 10nM, 20nM, and 80nM relative to the OD450nm of the empty-load treatment group was significantly higher than that of the empty-load treatment group, and the ratio of OD450nm of the mPEG-PLGA / FK506 drug-loaded nanoparticles treatment group with other concentrations relative to the OD450nm of the empty-load treatment group had a certain difference trend relative to the empty-load treatment group. This activity experiment was set up with 3 replicates for each concentration, and the experiment was repeated 3 times independently.

[0117] Determination of mortality of donor lung cells

[0118] Calcein was used to stain live cells and PI was used to stain dead cells, and the cell death rate of each group was calculated. Fig.15 As shown in the figure. The results of each group showed that the mortality rate of donor lung cells in the mPEG-PLGA / FK506 drug-loaded nanoparticles treatment group with tacrolimus drug concentrations of 10nM, 20nM, 40nM, 80nM, 100nM, 150nM, and 200nM was significantly lower than that in the empty load treatment group. Three replicate wells were set for each concentration in this experiment, and a total of three independent repeated experiments were performed.

[0119] The above experimental results indicate that mPEG-PLGA / FK506 drug-loaded nanoparticles have a significant protective effect on donor lung cells in an in vitro rejection reaction model.

[0120] Experimental Example 4: In vivo efficacy experiment of mPEG-PLGA / FK506 drug-loaded nanoparticles of the present invention

[0121] According to the method described in Example 1, mPEG-PLGA / FK506 drug-loaded nanoparticles were prepared using the optimal conditions screened out in Example 2 (PVA concentration of 1% PVA, mPEGPLGA concentration of 7 mg / ml, oil-water ratio of 2:8, volatilization speed of 2400 rpm, mass ratio of mPEG-PLGA and FK506 of 2:1, organic solvent of dichloromethane, high-speed shear speed of 15000 rpm, shear time of 30 min). When preparing mPEG-PLGA / FK506 drug-loaded nanoparticles, Cy5-labeled FK506 was used to replace ordinary FK506.

[0122] Empty nanoparticles were prepared according to the above method except that FK506 was not added.

[0123] Brown Norway rats were used as donors and Lewis rats as recipients for allogeneic lung transplantation. Routine anti-acute lung rejection treatment was performed in the first week after transplantation. At the end of the first week after surgery, Cy5 fluorescein was linked to tacrolimus to trace the drug, and 2 mg / kg mPEG-PLGA / FK506 drug-loaded nanoparticles were used for aerosol inhalation treatment. 30 minutes after aerosolization, the distribution of Cy5 fluorescence in the chest was displayed using a small animal in vivo imaging device to determine the distribution of the drug in the lung. The experiment was repeated 3 times.

[0124] result( Fig.16 ) showed that 2 mg / kg mPEG-PLGA / FK506 drug-loaded nanoparticles nebulized inhalation could be effectively diffused and distributed in both lungs.

[0125] Subsequently, Lewis rats were used as donors and recipients for syngeneic lung transplantation as negative control (Syn). BrownNorway rats were used as donors and Lewis rats were used as recipients for allogeneic lung transplantation. Routine anti-acute lung rejection treatment was performed in the first week after transplantation. At the end of the first week after surgery, empty nanoparticles (CR) and 2mg / kg (TAC-2), 4mg / kg (TAC-4), and 8mg / kg (TAC-8) mPEG-PLGA / FK506 drug-loaded nanoparticles were used for nebulization inhalation treatment three times a week. The recipient rats were killed in the fourth week after surgery to evaluate the progression of chronic transplant lung dysfunction. The evaluation method is as follows:

[0126] Preparation of paraffin sections:

[0127] The lungs (usually no thicker than 0.5 cm) are removed from fresh rat corpses and placed in a pre-prepared fixative (4% paraformaldehyde) to denature and coagulate the proteins in the tissues and cells to prevent autolysis of the cells after death or bacterial decomposition, thereby maintaining the original morphological structure of the cells.

[0128] Use alcohol from low to high concentration as dehydrating agent to gradually remove the water in the tissue block. Then put the tissue block in xylene, a transparent agent that is soluble in both alcohol and paraffin, to make it transparent. Use xylene to replace the alcohol in the tissue block before wax embedding.

[0129] Place the transparent tissue block in the melted paraffin and put it in a wax melting box to keep it warm. After the paraffin is completely immersed in the tissue block, embed it: first prepare a container, pour the melted paraffin, and quickly clamp the tissue block that has been soaked in paraffin and put it in. Cool and solidify into a block. The embedded tissue block must be hardened before it can be cut into very thin slices on the slicer.

[0130] The embedded wax block is fixed on the slicer and cut into thin slices, generally 5-8 microns thick. The slices are often wrinkled and need to be ironed flat in heated water, then attached to a slide and dried in a 45°C constant temperature box. Before staining, use xylene to remove the paraffin in the slices, then go through high-concentration to low-concentration alcohol, and finally distilled water to stain.

[0131] HE staining:

[0132] After being immersed in distilled water, place the slices in a hematoxylin aqueous solution for several minutes, then place them in acid water and ammonia water for color separation for several seconds each. Rinse with running water for 1 hour, then place them in distilled water for a while, and then place them in 70% and 90% alcohol for dehydration for 10 minutes each. Finally, place them in alcohol eosin staining solution for 2 to 3 minutes. The stained slices are dehydrated with pure alcohol, and then made transparent with xylene. Drop Canada gum on the transparent slices and cover them with coverslips for sealing. After the gum is slightly dry, affix labels.

[0133] Masson staining:

[0134] After being immersed in distilled water, the sections were stained with Regaud hematoxylin stain or Weigert iron hematoxylin stain for 5-10 minutes; differentiated with 1% hydrochloric acid alcohol for 5-15 seconds, and washed thoroughly with water; 0.1-1% lithium carbonate was added for 5 minutes to increase the degree of blueing, and washed with water; Masson Ponceau acid fuchsin solution was used for 5-10 minutes; washed with 2% glacial acetic acid aqueous solution for 1 minute; differentiated with 1% phosphomolybdic acid aqueous solution for 3-5 minutes, and washed with 2% glacial acetic acid aqueous solution for 1 minute; without washing, directly stained with aniline blue aqueous solution or 1% light green aqueous solution for 1-2 minutes; washed with 0.2% glacial acetic acid aqueous solution for 1 minute; dehydrated with 95% ethanol for 2-3 seconds, dehydrated with anhydrous ethanol 3 times for 5 seconds each time, transparentized with xylene 3 times for 1 minute each time, and sealed with neutral gum.

[0135] Semi-quantitative evaluation of pathology

[0136] Collagen fiber ratio (Fibrosis): Masson staining was used to evaluate the section. Ten 200-fold magnified fields were randomly selected from the whole lung. ImageJ was used to analyze the blue-stained collagen fiber area and the total area. The ratio of the blue-stained area to the total area was the collagen fiber ratio of each field. The collagen fiber ratio of the 10 random fields was averaged to obtain the collagen fiber ratio of the transplanted lung of the sample.

[0137] Vascular fibrosis rating: Masson-stained sections were used for evaluation, and two assessors blindly evaluated the fibrosis around the blood vessels in the whole field of view (divided into 0-4 grades). Among them, grade 0 represents no fibrosis around the blood vessels, grade 1 represents occasional fibrotic blood vessels in the whole field of view, grade 2 represents about 10% of the blood vessels with partial fibrosis, grade 3 represents about 10% of the blood vessels with partial fibrosis or more than 25% of the blood vessels with partial fibrosis, and grade 4 represents more than 25% of the blood vessels with complete fibrosis.

[0138] The International Society for Heart and Lung Transplantation A grade: HE-stained sections are used for evaluation, mainly evaluating the size and distribution of the peripheral mononuclear cell cuffs, which extend from the vascular adventitia to the adjacent alveolar septa, representing the overall situation of acute rejection. Among them, grade A0 represents: normal lung parenchyma without signs of mononuclear cell infiltration, hemorrhage or necrosis, grade A1 represents scattered, rare perivascular mononuclear cell infiltration in the lung parenchyma, especially venules, surrounded by small, round plasmacytoid and lymphocytes, forming a 2-3 cell thick annular cuff in the vascular adventitia. Grade A2 represents perivascular mononuclear cell infiltration that frequently appears around venules and arterioles, composed of small, round lymphocytes, plasmacytoid lymphocytes, macrophages and eosinophils. Grade A3 represents dense perivascular mononuclear cell infiltration, and inflammatory cells have infiltrated into the alveolar septa and alveolar cavities around blood vessels and bronchioles. Grade A4 represents the presence of diffuse perivascular, interstitial, and alveolar mononuclear cell infiltration, accompanied by significant alveolar cell damage and small vessel endotheliitis.

[0139] The results are as follows Fig.17 Pathological evaluation showed that aerosol inhalation of mPEG-PLGA / FK506 drug-loaded nanoparticles could effectively delay disease progression in a rat model of chronic transplant lung dysfunction.

[0140] In summary, the present invention provides a mPEG-PLGA / FK506 drug-loaded nanoparticle. The present invention selects specific preparation conditions to achieve the desired particle size, encapsulation rate and drug loading rate of the obtained nanoparticles, thereby ensuring the feasibility of pulmonary atomization of the nanoparticles; the nanoparticles themselves have good biosafety and have the effect of slowly releasing drugs, can adapt to chronic rejection reactions produced in lung transplantation, and can effectively delay the progression of chronic transplantation lung dysfunction; in addition, the dosage and frequency of drug use can be reduced, and the toxic and side effects of the drugs can be reduced, so it has good clinical application prospects.

Claims

1. The preparation method of mPEG-PLGA / FK506 drug-loaded nanoparticles is characterized by: It includes the following steps: (1) dissolving polyvinyl alcohol in water as the aqueous phase; (2) dissolving methoxy polyethylene glycol poly(lactic acid-co-glycolic acid) copolymer and tacrolimus in an organic solvent as an oil phase; (3) adding the oil phase of step (2) to the water phase of step (1) to prepare an emulsion; (4) adding the emulsion obtained in step (3) into the polyvinyl alcohol solution and stirring to evaporate the organic solvent, then centrifuging and drying to obtain nanoparticles.

2. The preparation method according to claim 1, characterized in that: In step (1), the concentration of polyvinyl alcohol in the aqueous phase is 5 to 50 mg / ml; and / or, in step (2), the concentration of methoxy polyethylene glycol polylactic acid-glycolic acid copolymer in the oil phase is 5 to 30 mg / ml; And / or, in step (2), the mass ratio of the methoxy polyethylene glycol polylactic acid-glycolic acid copolymer to tacrolimus is (1-6):1; And / or, in step (3), when the oil phase is added to the water phase, the volume ratio of the oil phase to the water phase is (2-4):8; And / or, in step (3), shearing is performed when the oil phase is added to the water phase, and ultrasonic dispersion is performed after the oil phase is added to the water phase.

3. The preparation method according to claim 2, characterized in that: In step (1), the concentration of polyvinyl alcohol in the aqueous phase is 10 mg / ml; and / or, in step (2), the concentration of methoxy polyethylene glycol polylactic acid-glycolic acid copolymer in the oil phase is 7 mg / ml; And / or, in step (2), the mass ratio of the methoxy polyethylene glycol poly(lactic acid-glycolic acid) copolymer to tacrolimus is 2:1; And / or, in step (2), the organic solvent is dichloromethane; And / or, in step (3), when the oil phase is added to the water phase, the volume ratio of the oil phase to the water phase is 1:

4.

4. The preparation method according to claim 2, characterized in that: In step (3), the shearing speed when the oil phase is added to the water phase is 12000-20000 rpm, and the shearing time is 15-60 min; preferably, the shearing speed is 15000 rpm, and the shearing time is 30 min; And / or, in step (3), the ultrasonic dispersion time after adding the oil phase into the water phase is 1 to 5 minutes.

5. The preparation method according to claim 1, characterized in that: In step (4), the polyvinyl alcohol solution is a polyvinyl alcohol aqueous solution with a concentration of 0.1%; and / or, in step (4), the volume ratio of the emulsion to the polyvinyl alcohol solution is 1:2; And / or, in step (4), the stirring temperature is 25 to 30° C., and the stirring time is 2 to 6 hours; And / or, in step (4), the stirring speed is 600 to 3000 rpm; And / or, in step (4), the centrifugal speed is 10000-12000 rpm, and the centrifugal time is 10-30 min; Preferably, in step (4), the stirring speed is 2400 rpm.

6. A mPEG-PLGA / FK506 drug-loaded nanoparticle, characterized in that: The invention is prepared by the preparation method described in any one of claims 1 to 5.

7. The mPEG-PLGA / FK506 drug-loaded nanoparticles according to claim 6, characterized in that: The average particle size of the mPEG-PLGA / FK506 drug-loaded nanoparticles is 100-210 nm.

8. Use of the mPEG-PLGA / FK506 drug-loaded nanoparticles according to claim 6 or 7 in the preparation of a nebulized drug delivery preparation.

9. The use according to claim 8, characterized in that: The drug delivery preparation is a pulmonary aerosol drug delivery preparation.

10. The use according to claim 9, characterized in that: The preparation is a preparation for treating chronic transplant lung rejection reaction after lung transplantation; Preferably, the preparation is a preparation for chronic allograft pulmonary dysfunction.

Citation Information

Patent Citations

  • Nanoparticulate tacrolimus formulations

    CN101132768A

  • Multifunctional nanoparticle preparation capable of preventing drug tolerance and preparation method thereof

    CN103494829A

  • PLGA / FK506 drug-loading nano microsphere and preparation method and application thereof

    CN110051652A

  • PLGA-PEG nano-particles applied to transplanted veins and preparation method of PLGA-PEG nano-particles

    CN117281960A

  • Dry powder formulations of tacrolimus administered by once daily (QD) inhalation

    CN117750945A